About

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization, founded in 2011 and headquartered in Songdo, Incheon, South Korea. As the biotech division of Samsung Group, its core services span from late discovery to large-scale commercial manufacturing, with a specialized focus on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines. The company, which is publicly traded, reported a significant revenue of KRW 4.55 trillion in 2024, solidifying its position in the biopharmaceutical industry.